Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

Lenalidomide gained Food and Drug Administration (FDA) approval for treatment of patients with relapsed or refractory multiple myeloma (MM) in combination with dexamethasone in June 2006. In April 2005, the FDA and patient advocacy groups requested an expanded access programme to both provide lenali...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Chen, Christine, Reece, Donna E, Siegel, David, Niesvizky, Ruben, Boccia, Ralph V, Stadtmauer, Edward A, Abonour, Rafat, Richardson, Paul, Matous, Jeffrey, Kumar, Shaji, Bahlis, Nizar J, Alsina, Melissa, Vescio, Robert, Coutre, Steven E, Pietronigro, Dennis, Knight, Robert D, Zeldis, Jerome B, Rajkumar, Vincent
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Publishing Ltd 2009
Matèries:
Haematological Malignancy
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2728892/
https://ncbi.nlm.nih.gov/pubmed/19545290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2009.07728.x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars